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Identity 




The PLD1 gene is composed of 27 exons (PLD1a) or 
26 exons (PLD1b) and introns spanning 209658 bp. It 
starts at 171318616 and ends at 171528273 (NCBI 
database: entrez gene: PLD1 phospholipase D1, 
phosphatidylcholine-specific (Homo sapiens)). 
Transcription 
PLD1 DNA has two transcripts by alternative splicing. 
(PLD1a: 27 exons, 5607 bp mRNA, 1074 amino acids, 
PLD1b: 26 exons, 5493 bp mRNA, 1036 amino acids) 
(NCBI database: NCBI Reference Sequence: 
NM_002662.3 (PLD1a), NM_001130081.1 (PLD1b)). 
Protein 
Description 
PLD1 (MW: about 120 kDa) contains the several 
conserved domains/regions (Hammond et al., 1995). 
PLD superfamily has a well-conserved HKD motif 
(HXK[X]4D[X]6GSXN), which is in conserved regions 
II and IV that mediate PLD enzymatic activity. In 
addition, the PX and PH domains are known to be 
implicated in interactions with other proteins and 
phosphoinositide 4,5-bisphosphate (PtdIns (4,5)P2), 
respectively (Sung et al., 1999). Recently, the PX and 
PH domains of PLD have been reported to be the core 
binding regions of PLD and to mediate its functions. 
For example, dynamin and µ2 showed the effects on 
EGFR-mediated endocytosis via R128/R197 of the 
PLD1-PX domain and R304 of the PLD1-PH domain, 
respectively (Lee et al., 2006; Lee et al., 2009b).  
 
Exons are represented by red rectangles and introns by lines. The picture is not represented by exact scale. 
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PX: Phox homology (PX) domain; PH: Pleckstrin homology (PH) domain; Loop: Loop region; I, II, III, IV: conserved regions I, II, III, and 
IV; The red arrow indicates the difference between PLD1a and PLD1b. 
 
Also, PLCgamma and munc18 can interact with the 
P161/P164 of the PLD1-PX domain and the C-terminal 
region (184~212 residues) of the PLD1-PX domain, 
respectively (Jang et al., 2003; Lee et al., 2004). These 
interactions occur in an EGF-dependent manner and 
contribute to the regulation of PLD activity. 
Furthermore, PKCalpha can phosphorylate the T147 of 
the PLD1-PX domain to increase PLD activity (Kim et 
al., 1999). In addition, to protein interactions, these 
domains can interact with phospholipids. Recently, it 
has been reported that phosphoinositide 3,4,5-
bisphosphate (PtdIns (3,4,5)P3 interacts with the R179 
of the PLD1-PX domain and can stimulate PLD 
activity (Lee et al., 2005). 
Phosphatidic acid-(PA) can also bind to PLD via a 
secondary lipid-binding pocket residue (R158) in the 
PLD1-PX domain (Stahelin et al., 2004). In addition, 
PLD1-PH domain also interacts with phosphoinositide 
4,5-bisphosphate (PtdIns (4,5)P2 (Hodgkin et al., 2000). 
It has been reported that this interaction can regulate 
PLD activity and localization. 
Expression 
PLD1 is ubiquitously expressed in a variety of tissues 
including brain, lung, heart, liver, adipose tissue, and 
spleen (Meier et al., 1999). The expression level of 
PLD1 is elevated in several cancer cells (Noh et al., 
2000; Buchanan et al., 2005). 
Localisation 
It is believed that PLD1 is primarily localized in 
perinuclear regions, such as, endoplasmic reticulum 
(ER), Golgi apparatus, and secretory vesicles (Jenkins 
et al., 2005). Several reports have suggested that PLD1 
is also localized in endosomes (early, late, and 
recycling) and lysomes (Toda et al., 1999; Hughes et 
al., 2001; Du et al., 2003). Furthermore, PLD1 can 
translocate to the plasma membrane in a signal-
dependent manner (Brown et al., 1998), and can be 
localized in specialized region (caveolae) of the plasma 
membrane. The C240/C241 residues of PLD1 are 
palmitoylated to localize at caveolae, and this 
localization is important for mediating EGF signaling 
(Han et al., 2002). Recently, it was reported that PLD1 
also has nuclear roles (Gayral et al., 2006). 
Function 
PLD1 is a phospholipid-hydrolyzing enzyme that can 
catalyze phosphatidylcholine (PC) to generate 
phosphatidic acid (PA) and choline. PA can function as 
a second messenger and can be converted to other  
biomolecules, such as, LPA and DAG (Jenkins et al., 
2005). PA can interact with a variety of molecules to 
recruit it to the membrane. For example, PA binds to 
mTOR-FRB domain and regulates its cell growth 
signaling activity (Fang et al., 2001), and can interact 
with PtdIns(4)P 5-Kinase (Honda et al., 1999); this 
latter interaction can modulate the generation of 
PtdIns(4,5)P2. Recently, it was been reported that PA 
can translocate SOS to the plasma membrane to 
mediate EGF signaling (Zhao et al., 2007). PLD can 
mediate many cellular phenomena, such as, 
proliferation, vesicle trafficking, cytoskeleton 
reorganization, and differentiation, and recently, Elvers 
et al. after a study on PLD1 knockout mice, reported 
that PLD1 can modulate thrombus formation via 
platelet aggregation (Elvers et al., 2010). 
Proliferation 
PLD can be activated by a variety of mitogenic signals 
- epidermal growth factor (EGF), platelet-derived 
growth factor (PDGF), vascular endothelial growth 
factor (VEGF), insulin, growth hormones, 
lysophosphatidic acid (LPA), and spingosine 1-
phosphate - all of which can directly bind with G-
protein coupled receptors (GPCR) and receptor-
tyrosine kinases (RTK). PLD activation via mitogenic 
signals can induce cell proliferation, cell survival, the 
suppression of cell cycle arrest, and the prevention of 
apoptosis (Foster et al., 2003; Lee et al., 2009a; Su et 
al., 2009). Furthermore, elevated PLD activity has been 
shown to transform cells (Buchanan et al., 2005). 
Vesicle trafficking 
It has been reported that PLD is critically involved in 
vesicle formation and trafficking, such as, in 
endocytosis, exocytosis, and vesicle formation from the 
trans-Golgi network (Cazzolli et al., 2006). PLD-
derived PA generation can recruit downstream 
molecules (PtdIns(4)P 5-Kinase) that are involved in 
vesicle fusion and mediate the inner membrane 
curvature (Jenkins et al., 2005). Many reports have 
suggested that PA generation by PLD can contribute to 
exocytosis (immune cell degranulation, 
neurotransmitter secretion, and EGF secretion) in 
various cell lines, such as, mast cells, adipocytes, and 
neuroendocrine cells. Furthermore, endocytosis 
(receptor mediated endocytosis and phagocytosis) also 
depends on PA generation by PLD (Humeau et al., 
2001; Hughes et al., 2004; Huang et al., 2005; Peng et 
al., 2005). Recently, we have been suggested that PLD 
protein can increase the GTPase activity of dynamin, 
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which is important for endocytosis, and that PLD itself, 
and not PA, can increase EGFR endocytosis (Lee et al., 
2006). 
Cytoskeletal reorganization 
PA generation by PLD activation has been shown to be 
a key regulator of cytoskeletal dynamics to induce cell 
adhesion, spreading, and migration. PLD can be 
activated by kinases (PKC and PtdIns(4)P 5-Kinase) 
and small G proteins (Rho, Rac, cdc42, Arf, and Ral) 
that mediate signaling essentially required for 
cytoskeletal reorganization (Rudge et al., 2009). 
Moreover, PLD-derived PA can translocate GTP-Rac 
to the plasma membrane and induce integrin-mediated 
cell spreading (Chae et al., 2008). 
Differentiation 
PLD appears to be involved in the differentiation of 
various cells. Prolonged PA generation by PLD 
activation is correlated with the differentiation of 
keratinocytes (Jung et al., 1999), and the PLD isozyme 
expression levels are increased during granulocytic 
differentiation (Di Fulvio et al., 2005). PLD is well 
known to have an essential role during neuronal cell 
differentiation (Kanaho et al., 2009). Recently, Yoon et 
al reported that PLD can induce myoblast 
differentiation via the secretion of IGF2 in an autocrine 
manner (Yoon et al., 2008). 
Homology 
A blast search produced the following results: 
85% sequence identity in Mus musculus. 
87% sequence identity in Rattus norvegicus. 
47% sequence identity in C. elegans. 




Several tumor cells (breast cancer, colon cancer) show 
elevated PLD1 expression and activity. For example, 
the expression and activity of PLD1 are upregulated in 
breast cancer tissue. Also, the expression of 
PLD1/PLD2 is upregulated in colon cancer (Noh et al., 
2000; Buchanan et al., 2005; Saito et al., 2007). 
Furthermore, a polymorphism of PLD2 was shown to 
be associated with the prevalence of colorectal cancer 
(Yamada et al., 2003). Increased PLD1 
activity/expression can transform rat fibroblasts. It has 
been shown that the mTor pathway can contribute to 
the growth and survival of cancer cells. Moreover, 
elevated PLD1 levels can increase the phosphorylation 
of S-6 kinase, which is a downstream molecule in mTor 
signaling (Hui et al., 2004). 
Recently, PLD1 was shown to activate Rheb, which is 
upstream of the GTPase of mTor (Sun et al., 2008). 
Furthermore, PLD has also been implicated in the 
invasion of tumor cells and in the secretion of matrix 
metalloproteinases (MMP) (Pai et al., 1994; Wakelam 
et al., 1997; Knoepp et al., 2008; Park et al., 2009). In 
particular, the upregulation of PLD1 by PMA was 
shown to increase the secretion of MMP9 in colon 
cancer cells (Kang et al., 2008). 
Alzheimer's disease 
Note 
The expression and activity of PLD1 is increased in the 
AD (Alzheimer Disease) brain. 
Beta-Amyloid precursor protein (beta-APP), which is 
involved in the pathogenesis of AD, has been shown to 
interact with PLD1-PH domain and elevated APP 
levels increased PLD activity in astroglioma cells (Jin 
et al., 2006; Jin et al., 2007). Also, the presenilins 
(PS1/PS2), which can mediate the proteolysis of beta-
amyloid precursor protein, have been shown to interact 
with PLD1. Furthermore, the generation of beta-
amyloid from beta-APP containing vesicles was found 
to be decreased by the overexpression of PLD1, which 
also promoted the budding out of beta-APP containing 
vesicles (Cai et al., 2006a; Cai et al., 2006b). Although 
evidence exists that PLD1 is associated with AD, the 
pathophysiological relationship between PLD1 and AD 
needs further study. 
To be noted 
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